Investor Centre

Pharmaxis today announced that it had submitted detailed grounds for re-examination of its Bronchitol EU marketing application for cystic fibrosis to the Committee for Medicinal Products for Human Use.The documents have been lodged following the formal request for re-examination submitted last month and subsequent dialogue between the Company and the new Rapporteurs appointed to lead the process.